Skip to main content
  • rainbow over text: 'thank you NHS'
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Ucb S.a. (UCB) NPV (CDI)

Sell:€89.56 Buy:€89.60 Change: €0.40 (0.44%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:€89.56
Buy:€89.60
Change: €0.40 (0.44%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:€89.56
Buy:€89.60
Change: €0.40 (0.44%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.

Contact details

Address:
Allee de la Recherche, 60
ANDERLECHT
1070
Belgium
Telephone:
+32 (2) 5599999
Website:
https://www.ucb.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
UCB
ISIN:
BE0003739530
Market cap:
€17.20 billion
Shares in issue:
188.58 million
Sector:
Pharmaceuticals
Exchange:
Euronext Brussels
Country:
Belgium
Currency:
Euro
Indices:
BEL 20

Key personnel

  • Jean-Christophe Tellier
    Chairman of the Executive Committee, Chief Executive Officer, Executive Director
  • Sandrine Dufour
    Chief Financial Officer, Executive Vice President, Member of the Executive Committee
  • Detlef Thielgen
    Executive Vice President, Chief Financial Officer and Corporate Development, Member of the Executive Committee
  • Jean-Luc Fleurial
    Chief Human Resource Officer, Executive Vice President, Member of the Executive Board
  • Dhavalkumar Patel
    Executive Vice President, Chief Scientific Officer, Member of the Executive Committee
  • Bill Silbey
    Executive Vice President, General Counsel
  • Emmanuel Caeymaex
    Executive Vice President, Immunology Patient Value Unit Head, Member of the Executive Committee
  • Iris Loew-Friedrich
    Executive Vice President and Chief Medical Officer, Member of the Executive Board
  • Kirsten Lund-Jurgensen
    Executive Vice President, Supply and Technology Solutions, Member of the Executive Board
  • Charl van Zyl
    Executive Vice President Neurology Solutions and Head of EU/International

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.